AEON — AEON Biopharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1837607 ·
Last close
$0.11
Market Cap
$5.66M
52W High
$1.45
52W Low
$0.11
ADV30
1,187,205
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,929,000 | -1,155,000 | 5,910,000 | 3,431,000 | 21,271,000 |
| Mar 2026 | 0 | — | -5,937,000 | -11,793,000 | 8,630,000 | 6,243,000 | 25,382,000 |
| Dec 2025 | 0 | — | -5,501,000 | -37,137,000 | 5,560,000 | 3,006,000 | 60,587,000 |
| Sep 2025 | 0 | — | -2,530,000 | -4,538,000 | 8,734,000 | 5,927,000 | 28,606,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,642,000
Investing CF
$0
Financing CF
$8,634,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-483,767,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,897,000
Pretax Income TTM
$-54,623,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,302,000 | -39,222,000 | 5,560,000 | 60,587,000 | -55,027,000 | -17,308,000 |
| Dec 2024 | 0 | -27,824,000 | 42,005,000 | 3,142,000 | 31,711,000 | -28,569,000 | -20,292,000 |
| Dec 2023 | — | — | — | 6,845,000 | 159,889,000 | -153,044,000 | — |
| Dec 2022 | 0 | -48,429,000 | -52,556,000 | 10,778,000 | 281,191,000 | -287,500,000 | -35,584,000 |
| Dec 2021 | 0 | -36,881,000 | -55,637,000 | — | — | — | -28,433,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-54,623,000
OpCashFlow TTM
—
Assets (Latest)
$5,910,000
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics, Inc. | $5.72M | $0.01 | — |
| INBP | INTEGRATED BIOPHARMA INC | $5.59M | $0.18 | — |
| GTBP | GT Biopharma, Inc. | $5.74M | $3.18 | — |
| INNPF | INNOCAN PHARMA Corp | $5.80M | $1.29 | — |
| ALZN | Alzamend Neuro, Inc. | $5.45M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
2026-11-09 13:00 · Yahoo
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
2026-10-09 20:15 · Yahoo
AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar
2026-10-05 09:36 · Yahoo
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
2026-09-09 12:00 · Yahoo
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
2026-08-24 12:00 · Yahoo
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 20:15 · Yahoo
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
2026-08-03 20:15 · Yahoo
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
2026-07-14 12:00 · Yahoo
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
2026-04-03 20:05 · Yahoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
2026-06-04 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.